K.N.Nandakumar1 Rajappan Chandra Satish Kumar2, , D.Sai balasubramanian3, S.Balasundar4 , D.Mothiswaran2, J.Narayanan5,S.S.Vishakan 6, V.Chitra5*, P.Venkataraman1*,
Abstract
:The growing prevalence of diabetic patients in recent times has been increasing globally and is also attributed as the most common metabolic disease. As a result of its lack in the control and management of disease condition seems to be still far from achieving success, especially due to the safetylimitations of currently available medicines. Toxicity studies serve as an important indicator in providing information on the toxic doses and to determine therapeutic indices of potential drugs. The study aimed to investigate the acute and subacute toxicity of cresvin-beta tablets, a polyherbal antidiabetic tablet formulation for 14 days and 28 days of repeated dose respectively for assessing the oral toxicity study in Wistar rats. From the acute toxicity findings, the approximately recorded acute lethal dose of of Cresvin beta suspension extract (LD50) in Wistar rats estimated to be above 2000 mg/kg. During this study period involving with investigations on acute and subacute toxicity tests were performed a period of 28 days and 14 days respectively. The findings exhibited no adverse signs of health complications or death. Histopathological modifications were observed for organs namely- heart, kidney and liver of the animals that were treated with Crevisin beta doses. The hematological parameters exhibited no statistical differences when comparing both the control and the Cresvin beta-treated group. In addition, the biochemical assays involved with estimation of ALP levels, AST levels, GLU, GLO, TBIL, BUN, TG, UA, CK and LDH were found to have statistically changed among the treatment groups. The findings are indicative that the reported Cresvin beta LD50 reported >2000 mg/kg body weight (BW), thereby based on the achieved findings, the study provided certain key information for the safety profile of Cresvin beta.
Keywords:
:#
References
1. Schneider, B.J., Naidoo, J., Santomasso, B.D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M.B., Brassil, K.J., Caterino, J.M., Chau, I. and Davies, M.J., 2021. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology, 39(36), pp.4073-4126.
2. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov. 2009;8(5):417–29.
3. Murai Y, Ohta T, Tadaki H, Miyajima K, Shinohara M, Fatchiyah F, Yamada T. Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model. Med Arch. 2017 Dec;71(6):380-384.
4. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843.
5. Surya, S., Salam, A. D., Tomy, D. V., Carla, B., Kumar, R. A., & Sunil, C. (2014). Diabetes mellitus and medicinal plants-a review. Asian Pacific Journal of Tropical Disease, 4(5), 337-347.
6. Li, Y., Kandhare, A.D., Mukherjee, A.A. and Bodhankar, S.L., 2019. Acute and sub-chronic oral toxicity studies of hesperidin isolated from orange peel extract in Sprague Dawley rats. Regulatory Toxicology and Pharmacology, 105, pp.77-85.
7. Petchi, R. R., Vijaya, C., & Parasuraman, S. (2014). Antidiabetic activity of polyherbal formulation in streptozotocin–nicotinamide induced diabetic Wistar rats. Journal of traditional and complementary medicine, 4(2), 108-117.
8. Rastogi, S. (2009). Poor quality and improper use: A review of common reasons of possible adversity in Ayurvedic practice. International Journal of Risk & Safety in Medicine, 21(3), 121-130.
9. World Health Organization. (2004). Guidelines for the regulation of herbal medicines in the South-East Asia Region (No. SEA-Trad. Med.-82). WHO Regional Office for South-East Asia.
10. Jonsson, M., Jestoi, M., Nathanail, A.V., Kokkonen, U.M., Anttila, M., Koivisto, P., Karhunen, P. and Peltonen, K., 2013. Application of OECD Guideline 423 in assessing the acute oral toxicity of moniliformin. Food and chemical toxicology, 53, pp.27-32.
11. Serbis, A., Giapros, V., Kotanidou, E. P., Galli-Tsinopoulou, A., & Siomou, E. (2021). Diagnosis, treatment and prevention of type 2 diabetes mellitus in children and adolescents. World Journal of Diabetes, 12(4), 344.
12. Scheen, A. J. (2021). Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opinion on Pharmacotherapy, 22(16), 2149-2165.
13. Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021). Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. Pharmaceuticals, 14(8), 806.
14. Bedi, O., & Krishan, P. (2020). Investigations on acute oral toxicity studies of purpurin by application of OECD guideline 423 in rodents. Naunyn-Schmiedeberg's Archives of Pharmacology, 393(4), 565-571.
